Literature DB >> 8750833

Expression of the neuropeptide Y Y1 receptor in human embryonic kidney 293 cells: ligand binding characteristics, in situ hybridization and receptor autoradiography.

Y Tong1, Y Dumont, S H Shen, H Herzog, J Shine, R Quirion.   

Abstract

The human neuropeptide Y Y1 receptor cDNA was transfected into human embryonic kidney 293 (HEK 293) cells and used to determine the selectivity of newly developed Y1 and Y2 radioligands in a model which expresses a single NPY receptor subtype. The Y1 receptor probe, [125I][Leu31,Pro34]PYY, binds with high afinity (KD of 0.4-0.6 nM) to Y1-transfected HEK 293 cells whereas the Y2 radioligand, [125I]PPY3-36 failed to demonstrate any significant labelling. Only non-selective (PYY) or selective Y1 receptor agonists behaved as potent competitors for [125I][Leu31,Pro34]PYY binding in transfected cells. Additionally, the efficacy of the transfection method used was evaluated at both the transcriptional and translational levels. In situ hybridization revealed the heterogeneous distribution of the NPY Y1 receptor mRNA expressed in transfected HEK 293 cells. Similarly, the levels of NPY Y1 binding sites per transfected cell varied as shown using [125I][Leu31,Pro34]PYY receptor autoradiography. Taken together, these results demonstrate that HEK 293 cells transfected with the NPY Y1 receptor cDNA expressed both the related receptor mRNA and protein albeit at different levels depending upon each transfected cell. Additionally, these data further establish the selectivity of the newly developed Y1 and Y2 radioligands.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8750833     DOI: 10.1016/0169-328x(95)00176-s

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  6 in total

1.  [(125)I]-GR231118: a high affinity radioligand to investigate neuropeptide Y Y(1) and Y(4) receptors.

Authors:  Y Dumont; R Quirion
Journal:  Br J Pharmacol       Date:  2000-01       Impact factor: 8.739

2.  BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist.

Authors:  Y Dumont; A Cadieux; H Doods; L H Pheng; R Abounader; E Hamel; D Jacques; D Regoli; R Quirion
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  Agonist- and antagonist-induced sequestration/internalization of neuropeptide Y Y1 receptors in HEK293 cells.

Authors:  Leng Hong Pheng; Yvan Dumont; Alain Fournier; Jean-Guy Chabot; Alain Beaudet; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

4.  BODIPY-conjugated neuropeptide Y ligands: new fluorescent tools to tag Y1, Y2, Y4 and Y5 receptor subtypes.

Authors:  Yvan Dumont; Pierrette Gaudreau; Manuela Mazzuferi; Daniel Langlois; Jean-Guy Chabot; Alain Fournier; Michele Simonato; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

Review 5.  Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system.

Authors:  J G Chabot; S Kar; R Quirion
Journal:  Histochem J       Date:  1996-11

6.  Development and characterization of a highly selective neuropeptide Y Y5 receptor agonist radioligand: [125I][hPP1-17, Ala31, Aib32]NPY.

Authors:  Yvan Dumont; Mira Thakur; Annette Beck-Sickinger; Alain Fournier; Rémi Quirion
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.